Código QR (código de barras bidimensional)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of zapnometinib: results from a phase I clinical study

IntroductionZapnometinib (ATR-002) is a selective MEK inhibitor designed to modulate the MAPK/ERK pathway, which plays a key role in viral infections and inflammatory diseases. Clinical characterization of its safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) is essential to sup...

ver descrição completa

Na minha lista:
Principais autores: Stephan Stenglein, Julian Volk, Yvonne Füll, Christian Reh, Steffen Haffner, Sebastian Canisius, Tim Overend, Oliver Planz
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2026-04-01
coleção:Frontiers in Pharmacology
Assuntos:
mek inhibitor
pharmacokinetics
phase I
safety
tolerability
zapnometinib
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fphar.2026.1743230/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados